LINEZOLID Pfizer gran 20 mg/ml p susp fl 150 ml
7680662500013
CH-66250
J01XX08
08.01.9.
Reimbursement limitations:
ZYVOXID
Traitement de la pneumonie nosocomiale,
des infections compliquées de la peau et des parties molles,
…
1 / 3
google
Details
- Product number
- 6625001
- CPT
- -
- Packaging group
- 150
- Unit
- ml
- Composition
- linezolidum 20 mg, saccharum 210.58 mg, acidum citricum, natrii citras anhydricus, cellulosum microcristallinum, carmellosum natricum, aspartamum 7 mg, xanthani gummi, mannitolum, E 211 2 mg, aromatica (Orange) cum ethanolum 0.2 mg et maltodextrinum, silica colloidalis anhydrica, aromatica (Pfefferminze), aromatica (Vanille) cum propylenglycolum et alcohol benzylicus et maltodextrinum, natrii chloridum, sorbitolum 8.76 mg, fructosum 3.36 mg, maltodextrinum, acidum glycyrrhizinicum, ammonii glycyrrhizas, triglycerida media, aromatica (Orangencrème) cum ethanolum et amylum modificatum et maltodextrinum, ad granulatum corresp. suspensio reconstituta 1 ml corresp. natrium 2.279 mg.
Articles (1)
Linezolid Pfizer 20 mg/ml, Granulat zur Herstellung einer Suspension zum Einnehmen
Granulat
150
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
20.0 MG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
210.58 MG | Substance | HBESI |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
7.0 MG | Substance | HBESI |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
2.0 MG | Substance | HBESI |
|
(N/A)
|
- | Substance | AROMA |
|
(N/A)
|
0.2 MG | Substance | HBESI |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | AROMA |
|
(N/A)
|
- | Substance | AROMA |
|
(N/A)
|
- | Substance | Hilfsstoff ohne Deklarationspflicht (Excipient sans obligation de déclaration) |
|
(N/A)
|
- | Substance | HBESI |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
8.76 MG | Substance | HBESI |
|
(N/A)
|
3.36 MG | Substance | HBESI |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | AROMA |
|
(N/A)
|
- | Substance | HBESI |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
2.279 MG | Substance | HBESI |
Reimbursement information
Public price
CHF 254.80
Specialties list
Yes
Generic
Yes
Reimbursement limitation
SL addition date:
01/11/2016
Authorization holder
Pfizer AG
8052 Zürich
Authorization information
- Swissmedic authorization number
- 66250
- Drug name
- Linezolid Pfizer, Granulat zur Herstellung einer Suspension zum Einnehmen
- Galenic form
- GRAS
- ATC Code
- J01XX08
- Authorization status
- Z
- Authorization category
- Category C
- Dispensation category
- A
- First authorization
- 09/06/2016
- Authorization expiration date
- 31/12/9999
- IT number
- 08.01.9.
- Domain
- Human medicine
Packaging details
- Description (FR)
- LINEZOLID Pfizer gran 20 mg/ml p susp fl 150 ml
- Description (DE)
- LINEZOLID Pfizer Gran 20 mg/ml f Susp Fl 150 ml
- Market launch
- 09/06/2016
- Narcotic (BTM)
- No
Original drug
Zyvoxid 20 mg/ml, Granulat zur Herstellung einer Suspension zum Einnehmen
GTIN:
7680555590022
CHF 279.75